StreetAlpha.app
Home › Stocks › CERS

Cerus Corp (CERS)

Healthcare
$1.85
▼ −2.63%
LAST CLOSE · NOV 20

Cerus makes the INTERCEPT Blood System, which is used to reduce pathogens in donated blood components for transfusion. It last closed at $1.85 on Nov 20, down 2.63% on the day. The next earnings report for CERS is expected around Mon, Jan 11, 2027. For the quarter ended Sep 2026, CERS reported EPS of $0.00 on revenue of $57.7M, with revenue up 9.5% from a year ago. Over its last 8 reports the stock moved an average of 14.0% the session after earnings. Over the last 12 months CERS insiders bought $0 of stock on the open market and sold $3.1M, according to SEC Form 4 filings.

AI Auto Pilots
Is CERS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CERS.

Key Stats

Last 12 months
Results
Revenue
$254.2M
Net income
−$7.3M
−2.9% margin
EPS (diluted)
−$0.04
Free cash flow
$494K
0.2% margin
Valuation
Market cap
$373.6M
202.0M shares
P/E
–
No P/E while losing money
Price to sales
1.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$16.4M
At Sep 30
Shareholder equity
$75.7M
Shares outstanding
202.0M
At Oct 16
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $159.5M$159.5MFY2021FY2022: $188.3M$188.3MFY2022FY2023: $186.8M$186.8MFY2023FY2024: $201.3M$201.3MFY2024FY2025: $233.8M$233.8MFY2025

From CERS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 2). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · Time not announced
Reported EPS
$0.00
Quarter ended Sep 2026
Year ago EPS
$0.00
Same quarter last year
Revenue
$57.7M
+9.5% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.01Dec '24Mar 2025: -$0.04Mar '25Jun 2025: -$0.03Jun '25Sep 2025: $0.00Sep '25Dec 2025: -$0.01Dec '25Mar 2026: -$0.01Mar '26Jun 2026: -$0.01Jun '26Sep 2026: $0.00Sep '26Latest $0.00
Revenue by quarter
Mar 2025: $43.2MMar '25Jun 2025: $52.4MJun '25Sep 2025: $52.7MSep '25Dec 2025: $85.4MDec '25Mar 2026: $53.7MMar '26Jun 2026: $57.4MJun '26Sep 2026: $57.7MSep '26Latest $57.7M
How CERS moved after its last 8 reports
Average move the session after a report ±14.0%
Nov 2, 2026After the close−0.8%
Jul 30, 2026After the close−25.6%
Apr 30, 2026After the close+34.0%
Mar 2, 2026After the close−15.8%
Jan 12, 2026Time not announced+10.2%
Nov 6, 2025After the close+21.3%
Aug 5, 2025After the close+0.8%
May 1, 2025After the close+3.9%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on CERSStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on CERS
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on CERS

Technical Analysis

CERS · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 15% below its 20 day and 24% below its 50 day average. It is 31% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 36), near oversold. The nearest support is the swing low (Nov 16) at $1.83, and the nearest resistance the Pivot at $1.87.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 8.1%/day
Key levels
$3.4752 week high+87.6%
$2.54100 day average+37.3%
$2.42200 day average+30.8%
$2.3050 day average+24.3%
$2.16Swing high (Nov 11)+16.8%
$2.1320 day average+15.1%
$1.93Pivot R1+4.3%
$1.87Pivot+1.1%
$1.85Last close
$1.83Swing low (Nov 16)−1.1%
$1.80Pivot S1−2.7%
$1.4752 week low−20.5%
Indicators
RSI (14)36.12Weak, oversold below 30Neutral
MACD-0.13Below its signal lineBearish
Stochastic9.7Near the bottom of its rangeOversold
ADX (14)26.4Trending down
Williams %R-95.7Oversold below −80, overbought above −20Oversold
CCI (20)-94.2Oversold below −100, overbought above 100Neutral
Rate of change−8.4%Change over 10 sessionsBearish
ATR (14)$0.15Typical daily range, 8.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CERS

What happened before

See how CERS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow CERS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How CERS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for CERSHow many large options trades hit CERS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

CERS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼76 buying vs 102 selling
  • ▲Held by funds +3.0 pts
  • ▼Funds holding -8
  • ▼Superinvestors: 2 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding179187−4.3%
In funds' top 1000–
Held by funds77.6%74.6%+3.0 pts
New / increased24 / 5236 / 71−29.0%
Reduced / sold out70 / 3253 / 16+47.8%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CERS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

CERS Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$3.1M19 sales · 6 insiders
98% of the selling was under pre-arranged trading plans.
2026-03 sold $2.1M2026-05 sold $100K2026-06 sold $648K2026-07 sold $53K2026-08 sold $90KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Aug 17Chrystal JensenChief Legal OfficerSale plan30,000$2.98$90K
Jul 16Vivek K JayaramanCEOSale plan16,666$3.16$53K
Jun 30William Mariner GreenmanPresident and CEOSale plan101,919$2.94$300K
Jun 30Kevin Dennis GreenCFOSale plan33,676$2.94$99K
Jun 30Chrystal JensenChief Legal OfficerSale plan24,329$2.94$72K
Jun 30Vivek K JayaramanCOOSale plan42,359$2.94$125K
Every insider buy and sale for CERS over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See CERS insider trades →

From SEC Form 4 filings by CERS's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CERS is in one of them and how their past CERS trades turned out.

CERS in the AI portfolios
Loading…

CERS News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CERS in an article yet. Here's the latest on the wider market.

CERS in the news

About Cerus

Cerus is a biomedical products company based in Concord, California. Its main product is the INTERCEPT Blood System, which is designed to reduce bloodborne pathogens in donated blood components intended for transfusion. The system is used to treat platelets and plasma, and a related version produces a fibrinogen complex for treating bleeding linked to fibrinogen deficiency. Cerus sells these products through its own sales force and distributors in several countries, while its red blood cell system remains in development.

Headquarters
Concord, CA